Operational Costs Compared: SG&A Analysis of argenx SE and Viridian Therapeutics, Inc.

A Comparative Analysis of SG&A Expenses: Argenx SE vs. Viridian Therapeutics, Inc.

In the ever-evolving landscape of biotechnology, operational efficiency is paramount. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent players: Argenx SE and Viridian Therapeutics, Inc., from 2014 to 2023. Over this period, Argenx SE's SG&A expenses surged by an astounding 16,600%, reflecting its aggressive expansion and strategic investments. In contrast, Viridian Therapeutics, Inc. experienced a more modest increase of approximately 1,200%, indicating a steady yet cautious growth trajectory.

Key Insights

• 2014-2017: Both companies maintained relatively low SG&A expenses, with Argenx SE starting at $4.2 million and Viridian at $7.8 million.
• 2018-2023: Argenx SE's expenses skyrocketed, peaking at $709 million in 2023, while Viridian's expenses reached $95 million.

This stark contrast highlights Argenx SE's rapid scaling efforts, positioning it as a formidable force in the biotech sector.